- Home
- DOUG vs MCRB Comparison
DOUG vs MCRB Comparison
Compare DOUG & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- MCRB
- Stock Information
- Founded
- DOUG 1911
- MCRB 2010
- Country
- DOUG United States
- MCRB United States
- Employees
- DOUG N/A
- MCRB N/A
- Industry
- DOUG Building operators
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- MCRB Health Care
- Exchange
- DOUG Nasdaq
- MCRB Nasdaq
- Market Cap
- DOUG 142.2M
- MCRB 141.9M
- IPO Year
- DOUG N/A
- MCRB 2015
- Fundamental
- Price
- DOUG $1.95
- MCRB $0.80
- Analyst Decision
- DOUG
- MCRB Buy
- Analyst Count
- DOUG 0
- MCRB 4
- Target Price
- DOUG N/A
- MCRB $5.63
- AVG Volume (30 Days)
- DOUG 657.1K
- MCRB 844.5K
- Earning Date
- DOUG 02-27-2025
- MCRB 03-04-2025
- Dividend Yield
- DOUG N/A
- MCRB N/A
- EPS Growth
- DOUG N/A
- MCRB N/A
- EPS
- DOUG N/A
- MCRB N/A
- Revenue
- DOUG $966,442,000.00
- MCRB $126,325,000.00
- Revenue This Year
- DOUG $5.28
- MCRB N/A
- Revenue Next Year
- DOUG $16.40
- MCRB N/A
- P/E Ratio
- DOUG N/A
- MCRB N/A
- Revenue Growth
- DOUG 1.86
- MCRB 12856.41
- 52 Week Low
- DOUG $1.00
- MCRB $0.54
- 52 Week High
- DOUG $2.98
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- DOUG 51.38
- MCRB 46.38
- Support Level
- DOUG $2.00
- MCRB $0.81
- Resistance Level
- DOUG $2.19
- MCRB $0.84
- Average True Range (ATR)
- DOUG 0.14
- MCRB 0.04
- MACD
- DOUG 0.01
- MCRB 0.00
- Stochastic Oscillator
- DOUG 42.86
- MCRB 45.58
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.